AbbVie’s Humira is nearing its international peak, and what goes up must come down. But investors don't need to worry, one analyst argues.

Novartis plans to cut 500 jobs in areas like “traditional manufacturing" in Switzerland over the next 18 months and add jobs in high-tech areas.

Johnson & Johnson had a "disappointing" first quarter, but its fortunes for the rest of the year—and beyond—are looking up, partly in thanks to…

A U.S. appeals court sided with Biogen in a lawsuit claiming execs weren't open with investors about Tecfidera's sales trajectory after the death of…

The White House budget director has suggested extending to Medicare the same kinds of rebates that drugmakers are required to provide to Medicaid.

Former Allergan Chairman Paul Bisaro will use his tested strategy of M&A and consolidation in his efforts to restore Impax Laboratories' fiscal health…

Mylan thought a series of recent deals would deliver future growth, but it's facing new pressures now—and may just have to rely on more M&A.

The Teva divestment rumors are true. The company wants to sell off its women’s health and European oncology and pain businesses to pay down debt.

Financials